

A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma

Authors

Noa Biran,¹⁻³ Eli Zolotov,⁴ David Vesole,¹⁻³ Harsh Parmar,¹⁻³ Pooja Phull,¹⁻³ Kimberley Doucette,⁵ Patrick Roney,⁶ Jaeil Ahn,⁶ Rena Feinman,⁷ Joshua Zenreich,¹ Palka Anand,¹ Monique Pace,¹ Alexandra Della Pia,¹ Bianca DeAgresta,¹ Lisa Biamonte,¹ Adolfo Aleman,¹ Ella Rutanen,⁵ Aimee Chappell,¹ Susan Kumka¹ and David S. Siegel¹⁻³

¹John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; ²Division of Multiple Myeloma, Hackensack University Medical Center, Hackensack, NJ; ³Department of Oncology, Hackensack Meridian School of Medicine, Nutley, NJ; ⁴Department of Internal Medicine, Hackensack University Medical Center, Hackensack, NJ; ⁵Georgetown University Medical Center, Washington, DC; ⁶Department of Biostatistics, Bioinformatics, and

Biomathematics, Georgetown University, DC and ⁷Hackensack Meridian Health Center for Discovery and Innovation, Nutley, NJ, USA

Correspondence:
N. BIRAN - Noa.Biran@hmn.org

<https://doi.org/10.3324/haematol.2024.287053>

Received: November 27, 2024.
Accepted: March 27, 2025.
Early view: April 3, 2025.

©2025 Ferrata Storti Foundation

Published under a CC BY-NC license



A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma

Noa Biran, Eli Zolotov, David Vesole, Harsh Parmar, Pooja Phull, Kimberley Doucette, Patrick Roney, Jaeil Ahn, Rena Feinman, Joshua Zenreich, Palka Anand, Monique Pace, Alexandra Della Pia, Bianca DeAgresta, Lisa Biamonte, Adolfo Aleman, Ella Rutanen, Aimee Chappell, Susan Kumka, and David S. Siegel

Supplementary Data:

Supplementary Table 1. Adverse Events Associated with daratumumab, selinexor, and dexamethasone.

Supplementary Figures:

Supplementary Figure 1. Study schema.


Supplementary Figure 2. Heatmap for FACT-MM questionnaire.

Supplementary Table 1. Adverse Events Associated with daratumumab, selinexor, and dexamethasone.

Adverse Events	Grade N=10 n (%)	
	Grade 1-2	Grade 3
General		
Fatigue / malaise / weakness	9 (90)	1 (10)
Dehydration	1 (10)	1 (10)
Bruising	2 (20)	0 (0)
Dizziness	1 (10)	0 (0)
Weight loss	1 (10)	0 (0)
Edema	1 (10)	1 (10)
Headache	1 (10)	0 (0)
Head injury	0 (0)	1 (10)
Hyperglycemia/diabetes	1 (10)	0 (0)
Hypotension	1 (10)	0 (0)
Urinary frequency	1 (10)	0 (0)
Left Arm/Chin	1 (10)	0 (0)
Soft tissue mass	1 (10)	0 (0)
Throat phlegm/pain	1 (10)	0 (0)
Hematological		
Anemia	4 (40)	0 (0)
Neutropenia	1 (10)	1 (10)
Thrombocytopenia	4 (40)	1 (10)
Infections		
Respiratory tract infections	8 (80)	2 (20)
Gastrointestinal	1 (10)	0 (0)
Others	3 (30)	0 (0)
Sepsis	2 (20)	2 (20)
Gastrointestinal		
Abdominal pain	1 (10)	1 (10)
Anorexia	3 (30)	0 (0)
Constipation	1 (10)	0 (0)
Diarrhea	4 (40)	0 (0)
Dyspepsia / GERD	3 (30)	0 (0)
Nausea / vomiting	5 (50)	1 (10)
Respiratory		
Cough	2 (20)	0 (0)
Dyspnea	1 (10)	0 (0)
Acute Hypoxic Respiratory Failure	1 (10)	1 (10)

Immune-mediated toxicity Dermatitis	1 (10)	0 (0)
Psychiatric Agitation Depression	2 (20) 1 (10)	0 (0) 1 (10)
Musculoskeletal Lower extremity DVT Musculoskeletal/bone cramps/pain	1 (10) 3 (30)	0 (0) 0 (0)
Neurology Neuropathy Syncope Parosmia Tremor	1 (10) 1 (10) 1 (10) 1 (10)	0 (0) 1 (10) 0 (0) 0 (0)
Laboratory abnormalities Transaminitis Increased BUN/Creatinine Hyperkalemia Hyperuricemia Hypomagnesemia Hyponatremia Hypophosphatemia Increased Lipase Lactic acidosis	3 (30) 3 (30) 2 (20) 2 (20) 3 (30) 9 (90) 2 (20) 1 (10) 1 (10)	1 (10) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (10) 1 (10)

Respiratory tract infections include COVID-19, Influenza A, Parainfluenza 3, Parainfluenza A-1, and Pneumonia. Gastrointestinal infections include C. difficile infection. Other infections include salivary gland infection, shoulder hardware infection, and conjunctivitis.



Supplementary Figure 1. Study schema.

Supplementary Figure 2. Heatmap for FACT-MM questionnaire. Responses were completed at screening (n=9), cycle 2 (n=6), cycle 3 (n=5), cycle 4 (n=5), cycle 5 (n=2), cycle 6 (n=2), cycle 7 (n=2), cycle 8 (n=2), cycle 9 (n=2), cycle 10 (n=1), and cycle 11 (n=1).